Clincosm LogoSign in Get a demo

CAN03: Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures

Sponsor
University of California, San Francisco (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06030674
Collaborator
(none)
200
Enrollment
1
Location
1
Arm
33.9
Anticipated Duration (Months)
5.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an unblinded pilot study of an environmental exposure to secondhand cannabis smoke in one group of healthy nonsmokers.

Condition or Disease Intervention/Treatment Phase
  • Other: Secondhand cannabis emissions/smoke exposure
 N/A

Detailed Description

The goal is to gather accurate information on uptake of smoke toxicants from cannabis exposures in the real world. The investigators will be taking healthy nonsmokers to public places where people are consuming cannabis and measuring their uptake of cannabinoids.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is an unblinded pilot study of an environmental exposure in one group.This is an unblinded pilot study of an environmental exposure in one group.
Masking:
None (Open Label)
Masking Description:
The exposure cannot be masked or blinded. Data analysts and chemists will be blinded.
Primary Purpose:
Basic Science
Official Title:
Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2025
Anticipated Study Completion Date :
Jun 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exposure to secondhand cannabis smoke in public places

The research staff and participants will travel together to a public location by either ride share vehicles, taxis or public transit. The study will arrange and pay for the transit. Staff and participants will be exposed to ambient air in public places where cannabis products are being consumed by smoking, vaporizing or dabbing. Participants will remain in the company of the laboratory staff throughout the exposure. The exposures will last 0.5-4 hours, depending on the nature and duration of the event. Staff and participants will travel together back to the laboratory for the post-exposure study measures.

Other: Secondhand cannabis emissions/smoke exposure
This is an environmental exposure performed in public places where people are consuming cannabis.

Outcome Measures

Primary Outcome Measures

  1. Change in the concentration of urinary cannabinoid metabolites in health nonsmokers exposed to cannabis smoke and emissions [Baseline (before exposure) and the morning after exposure, up to 22 hours.]

    The concentration of 11-Nor-9-carboxy-THC will be measured in urine with LC/MS-MS. The LOQ for this assay is 15 pg/ml. Anticipated changes in concentration are from BLOQ to 0.5-20 ng/ml. The duration of the exposures will depend on the event or venue at which exposures occur, ranging from 30 minutes to 4 hours. The investigators will compare the concentration of 11-Nor-9-carboxy-THC in participants' urine before exposure to concentrations in the first void of the morning after the day of exposure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Adult nonsmokers, aged 21-50, who:

  • Are healthy on the basis of medical history

  • Have systolic blood pressure <150

  • Have diastolic blood pressure <100

  • Have BMI between 18.1 and 34.9

  • Able to perform moderate exercise,

  • Are not exposed to tobacco or cannabis SHS in their daily lives. (Nonsmoking status and low SHS exposure are determined by self-report on the screening questionnaire, salivary cotinine < 10 ng/ml and THC < 50 ng/m and exhaled CO2 below 4 ppm)

Exclusion Criteria:

  • Current use of cannabis products, including CBD and edible THC products

  • Regular exposure to secondhand tobacco or cannabis smoke

  • Positive SARS-CoV-2 antibody test

  • Age 18 < or > 50

  • Physician diagnosis of asthma, heart disease, hypertension, thyroid disease, diabetes, renal or liver impairment or glaucoma.

  • Unstable psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder) or current use of more than two psychiatric medications

  • Systolic blood pressure > 150

  • Diastolic blood pressure > 100

  • Pregnancy or breastfeeding (by urine hCG and/or history)

  • Alcohol or illicit drug dependence within the past 5 years

  • BMI > 35 and < 18

  • Current illicit drug use (by history or urine test)

  • More than 1 pack year smoking history

  • Ever a daily marijuana smoker

  • Smoked anything within the last 2 months

  • Occupational exposure to smoke, dusts OR fumes

  • Concurrent participation in another clinical trial

  • Unable to communicate in English

  • No social security number

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zuckerberg San Francisco General Hospital San Francisco California United States 94110

Sponsors and Collaborators

  • University of California, San Francisco

Investigators

  • Principal Investigator: Suzaynn F Schick, University of California, San Francisco

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT06030674
Other Study ID Numbers:
  • T32IR4867
First Posted:
Sep 11, 2023
Last Update Posted:
Sep 11, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of California, San Francisco
Nonsmokers
Secondhand cannabis smoke
Environmental cannabis
Exposure
Additional relevant MeSH terms:
Marijuana Abuse

Study Results

No Results Posted as of Sep 11, 2023